Octostim (Desmopressin Acetate)

Desmopressin acetate acts as a selective agonist of the vasopressin V2 receptors in the kidney, enhancing water reabsorption and concentrating urine. It also stimulates the release of von Willebrand factor and factor VIII from endothelial cells, thereby supporting normal haemostasis without directly affecting platelet function.

The dosage of Octostim is individualized and determined by the prescribing healthcare professional based on the specific indication, patient age, weight, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Octostim should be used during pregnancy or lactation only if the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers will evaluate the clinical situation and may recommend alternative therapies when safer options are available.

To request Octostim, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Octostim is a generic formulation of desmopressin acetate, offering the same pharmacological profile as other branded or generic desmopressin products. Differences may lie in manufacturing standards, packaging, and regulatory approvals, but the active ingredient, mechanism of action, and clinical uses remain consistent across products.

Octostim should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Octostim is supplied as an oral tablet that patients swallow with water, typically once or twice daily as directed by the prescriber. For specific indications, the healthcare provider may adjust the timing relative to meals or fluid intake to optimise therapeutic effect.

The most serious risks include severe hyponatraemia, which can lead to seizures, coma, or death, and water intoxication from excessive fluid retention. Patients should be monitored for rapid weight gain, low serum sodium, and neurological symptoms, and fluid intake should be restricted as advised.

Octostim is contraindicated in patients with known hypersensitivity to desmopressin acetate, uncontrolled hyponatraemia, severe renal impairment, or those who are unable to adhere to fluid restriction guidelines. It should also be avoided in individuals with a history of water intoxication or certain cardiovascular conditions without medical supervision.